Abstract
At a single medical center, we identified 60 cases of coccidioidomycosis that were coincident with COVID-19 infection. Among these, seven patients developed new or clinically progressive coccidioidomycosis. Receipt of dexamethasone for COVID-19 infection was the only significant risk factor for the progression or development of clinically active coccidioidomycosis in this cohort. All patients survived and none developed disseminated coccidioidomycosis.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 199-204 |
| Number of pages | 6 |
| Journal | Mycopathologia |
| Volume | 187 |
| Issue number | 2-3 |
| DOIs | |
| State | Published - Jun 2022 |
| Externally published | Yes |
Bibliographical note
Publisher Copyright:© 2022, The Author(s), under exclusive licence to Springer Nature B.V.
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Coccidioidomycosis
- COVID-19
- Fungal infections
- SARS-CoV-2
Fingerprint
Dive into the research topics of 'Coccidioidomycosis and COVID-19 Infection. An Analysis from a Single Medical Center Within the Coccidioidal Endemic Area'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS